Topics

Companies Related to "Small Molecule Shows Marked Activity Against Ibrutinib Resistant∨derfield=score∨derval=DESC" [Most Relevant Company Matches] [Advanced Search Results] RSS

02:12 EDT 19th July 2019 | BioPortfolio

Here are the most relevant search results for "Small Molecule Shows Marked Activity Against Ibrutinib Resistant∨derfield=score∨derval=DESC" found in our extensive corporate database of over 50,000 company records.

Showing "Small Molecule Shows Marked Activity Against Ibrutinib Resistant" Companies 1–25 of 2,500+

Friday 19th July 2019

Algiax Pharmaceuticals

Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.


Thursday 18th July 2019

DSFederal

Based in Rockville, Maryland, DSFederal is an award-winning woman-owned small business that combines scientific expertise with leading-edge technologies in the areas of data analytics and data science, program management, workforce transformation and information technology to deliver better outcomes for the health and safety of our nation. Since 2007, DSFederal has been helping its federal custom...

Wednesday 17th July 2019

Frequency Therapeutics, Inc.

Frequency Therapeutics is a biotech company focused on developing small molecule drugs that stimulate cells in the body to reverse biological deficits and restore healthy tissue. Through the transitory activation of these cells, Frequency aims to develop therapies that can enable disease modification without the complexity of genetic engineering. Our development candidates use a proprietary combi...


Orum Therapeutics, Inc.

Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibody therapeutics. In contrast to other approaches, Orum...

Tuesday 16th July 2019

Ra Pharmaceuticals and Camurus AB

Ra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com.

Thursday 11th July 2019

A-TEK, Inc.

Headquartered in McLean, VA, A-TEK is comprised of a team of experts in managing the data that drives federal missions. A woman-owned small business with employees located in 12 states and 19 cities nationwide, A-TEK is a 23-year partner to U.S. government agencies including the NIH National Library of Medicine, and the Departments of Homeland Security, Justice, and Commerce. A-TEK delivers scien...

Monday 8th July 2019

Silicon Therapeutics

Silicon Therapeutics (“SiTX”) is a physics-driven drug discovery company focused on small molecule therapeutics for cancer that target innate immunity to “light the spark” within immunologically cold tumors. The company’s unique computational physics-based platform can accurately simulate the physical motion and properties of biological targets at atomistic resolution to ...

OncoSenX, Inc.

OncoSenX is a late preclinical-stage oncology company developing therapeutics to kill cancer cells based on their genetics. Headquartered in Seattle, Washington, the company’s technology platform targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA approach. For more information, visit www.oncosenx.com.

Friday 5th July 2019

Eurofins Spinnovation Analytical B.V.

Spinnovation Biologics is a division of Spinnovation Analytical BV (Nijmegen, The Netherlands, www.spinnovation-analytical.com). Spinnovation is a <!--LGfEGNT2Lhm-->contract research organization expert in delivering analytical service to the Industry (Pharmaceuticals, Chemicals/Polymers, <!--LGfEGNT2Lhm-->Food Products). Its expertise and core activity focuses on the use of Nuclea...

Tuesday 2nd July 2019

Blue River PetCare

Founded in 2009, Blue River is a multi-state owner and operator of high-quality veterinary hospitals, focusing primarily on general practice small companion animal medicine. Blue River seeks to acquire veterinary practices that have established businesses in their respective communities and enjoy a loyal following among pet owners.

Monday 1st July 2019

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of small molecule drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across m...

RevoluGen

RevoluGen is a small, UK based molecular chemistry research and development company that specialises in HMW-DNA isolation and purification from cell samples specifically for long-read sequencing applications. The combined Fire Monkey / Fire Flower product is RevoluGen’s disruptive first product. Using an innovative combination of chemistry and a spin-column process, RevoluGen has married the...

Thursday 27th June 2019

Caspio

Caspio is the leading low-code development platform for online database applications, embraced by business professionals for its ease of use and trusted by IT professionals for its security, compliance and scalability. Thousands of customers rely on Caspio to make their organization more agile and customer-centric — freeing themselves from comp...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule d...

Morphic Holding, Inc.

Morphic Therapeutic, Inc. is a biopharmaceutical company applying its proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Morphic has developed an exclusive technology platform by...

Tuesday 25th June 2019

Advanced IT Concepts (AITC)

AITC is an 8a minority and Service-Disabled Veteran Owned Small Business founded by former military information technology (IT) professionals. AITC assists government and private sector customers through systems design, engineering, test, integration and implementation of innovative solutions that draw upon information technology solutions in network, security, training, collaboration, communicat...

Monday 24th June 2019

Atomwise, Inc.

Atomwise, Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than one hundred universities and hospitals in more than 20 countries across the world. Atomwise has ra...

Friday 21st June 2019

Alnylam Biotherapeutics

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessi...

Wednesday 19th June 2019

EnChroma, Inc.

EnChroma, Inc. develops lens technologies and high-performance eyewear for color blindness. Co-founded by a Ph.D. glass scientist and UC Berkeley educated mathematician, EnChroma invented award-winning glasses for color blindness that combine the latest in color perception neuroscience and lens innovation to enable access to color for all. Established in B...

Monday 17th June 2019

Expansion Therapeutics, Inc.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at The Scripps Research Institute, Expansion has assembled the intellectual property, know-how, ...

Wednesday 12th June 2019

OnKure, Inc.

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenv...

Prelude Therapeutics

Prelude Therapeutics is a privately held, clinical-stage biopharmaceutical company based in Wilmington, DE. Prelude is focused on the discovery and development of small molecule agents targeting novel molecular mechanisms that drive cancer cell growth, survival and resistance to current treatments. For more information, please visit www.preludetx.com.

Tuesday 4th June 2019

Milliken & Company

Milliken’s roots date back to 1865 when Seth Milliken and William Deering founded Deering Milliken Company, a small woolen fabrics company in Portland, Maine. Deering soon left to start his own company. In 1868, Seth Milliken moved the company headquarters to New York City, at that time the heart of the American Textile Industry. In 1884, the company invested in a new facility in Pacolet, S...

Monday 3rd June 2019

Qurient Co. Ltd.

Qurient is a clinical-stage biopharmaceutical company listed in Korea Exchange (KRX 115180). Qurient has two programs in clinical development and one program in the IND enabling stage. Q301 is a topical leukotriene inhibitor for atopic dermatitis in a Phase 2b clinical trial in the United States. Q702 is a Axl/Mer/CSF1R triple inhibitor for immune-oncology...

Day Zero Diagnostics, Inc.

Day Zero Diagnostics, Inc., based in Boston, is pioneering a new class of infectious disease diagnostics using whole genome sequencing and machine learning to combat the risk of antibiotic-resistant infections. The company was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital. The company is r...


More From BioPortfolio on "Small Molecule Shows Marked Activity Against Ibrutinib Resistant∨derfield=score∨derval=DESC"

Quick Search

Corporate Database Quicklinks